Long-term outcomes of endoscopic papillectomy for ampullary adenoma with high-grade dysplasia or adenocarcinoma: a propensity score-matched analysis

Surg Endosc. 2023 May;37(5):3522-3530. doi: 10.1007/s00464-022-09856-w. Epub 2022 Dec 31.

Abstract

Background: Evidence of endoscopic papillectomy (EP) for ampullar adenoma with high-grade dysplasia (HGD) or adenocarcinoma is insufficient. Here we investigated the long-term outcomes of the advanced ampullary tumors treated by EP with careful surveillance comparing to subsequent surgery after EP.

Methods: Patients treated with EP for ampullary adenoma with HGD or adenocarcinoma from the multi-center retrospective Korean cohort of ampulla of Vater tumor were categorized into EP alone versus EP with subsequent surgery groups. The overall survival (OS) and recurrence-free survival (RFS) were analyzed for unmatched and matched cohorts using propensity score with nearest neighbor method.

Results: During a median 43.3 months of follow-up, 5-year OS was not significantly different between the EP alone and EP surgery groups (91.9% vs. 82.3%, P = 0.443 for unmatched cohort; 89.2% vs. 82.3%, P = 0.861 for matched cohort, respectively). Furthermore, 5-year RFS was not significantly different between the two groups (82.1% vs. 86.7%, P = 0.520 for unmatched cohort; 66.1% vs. 86.7%, P = 0.052 for matched cohort, respectively). However, the patients with positive both (lateral and deep) margins showed significantly poorer survival outcomes than those with negative margins within the EP alone group (P = 0.007).

Conclusion: EP alone with careful surveillance showed comparable survival outcomes to those of EP with subsequent surgery for ampullar HGD or adenocarcinoma. Resection margin status could be a parameter to determine whether to perform subsequent radical surgery after EP.

Keywords: Adenocarcinoma; Ampulla of Vater; Carcinoma in situ; Endoscopic mucosal resection; Survival rate.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adenocarcinoma* / pathology
  • Adenocarcinoma* / surgery
  • Adenoma* / pathology
  • Ampulla of Vater* / pathology
  • Ampulla of Vater* / surgery
  • Common Bile Duct Neoplasms* / pathology
  • Duodenal Neoplasms* / pathology
  • Humans
  • Liver Neoplasms* / pathology
  • Margins of Excision
  • Pancreatic Neoplasms* / pathology
  • Propensity Score
  • Retrospective Studies
  • Treatment Outcome